Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $167.71 USD
Change Today +1.05 / 0.63%
Volume 466.3K
BCR On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BCR) Snapshot

Open
$167.30
Previous Close
$166.66
Day High
$168.46
Day Low
$166.25
52 Week High
01/23/15 - $180.35
52 Week Low
04/23/14 - $132.81
Market Cap
12.5B
Average Volume 10 Days
578.4K
EPS TTM
$7.58
Shares Outstanding
74.3M
EX-Date
01/22/15
P/E TM
22.1x
Dividend
$0.88
Dividend Yield
0.52%
Current Stock Chart for CR BARD INC (BCR)

cr bard inc (BCR) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BCR) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products that include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as other products, such as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,900 Employees
Last Reported Date: 02/18/15
Founded in 1907

cr bard inc (BCR) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $594.5K
Group President
Total Annual Compensation: $594.5K
Group President
Total Annual Compensation: $592.1K
Compensation as of Fiscal Year 2014.

cr bard inc (BCR) Key Developments

CryoLife Provides Update on PerClot Litigation

CryoLife, Inc. provided an update on its ongoing litigation with C.R. Bard, Inc. and certain of its subsidiaries regarding PerClot. The U.S. District Court for the District of Delaware has allowed CryoLife's declaratory judgment lawsuit against C.R. Bard's Medafor, Inc. subsidiary to proceed. The Court also granted Medafor's motion for a preliminary injunction with respect to CryoLife's marketing and sale of PerClot Topical in the U.S. CryoLife is currently awaiting the Court's order, which it expects will provide details regarding the scope of the injunction. In April 2014, CryoLife filed a declaratory judgment lawsuit against C.R. Bard and certain of its subsidiaries, including Medafor, requesting that the Court declare that CryoLife's manufacture, use, offer for sale, and sale of PerClot in the U.S. does not and would not infringe Medafor's U.S. Patent No. 6,060,461. In addition CryoLife requested that the Court declare that the claims of the '461 Patent are invalid. In September 2014, Medafor filed a motion for a preliminary injunction against CryoLife.

CR Bard Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 11:00 AM

CR Bard Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 11:00 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Christopher S. Holland, Chief Financial Officer and Senior Vice President.

CR Bard Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 02:50 PM

CR Bard Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 02:50 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Timothy M. Ring, Chairman, Chief Executive Officer and Chairman of Executive Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $167.71 USD +1.05

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr517.50 DKK +3.00
Edwards Lifesciences Corp $143.68 USD +1.78
Endo International PLC $90.04 USD +2.23
Mettler-Toledo International Inc $323.29 USD +4.41
Terumo Corp ¥3,225 JPY -45.00
View Industry Companies
 

Industry Analysis

BCR

Industry Average

Valuation BCR Industry Range
Price/Earnings 44.4x
Price/Sales 3.8x
Price/Book 6.9x
Price/Cash Flow 42.1x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.